Nuclera appoints Joseph Bertelsen as Chief Commercial Officer

Nuclera, the biotechnology company enabling rapid protein expression and purification screening through its benchtop protein platform, today announced the appointment of Joseph Bertelsen as Chief Commercial Officer (CCO). With over 20 years’ commercial leadership experience in the life science tools and drug development industries, Joseph brings an extensive sales record that will be instrumental to the commercial launch strategy and explosive adoption of Nuclera’s eProtein Discovery™ platform.

Joseph joins Nuclera from the Institute for Protein Innovation, a research institute focused on providing synthetic antibodies and protein expertise, where he was the Director of Commercialization responsible for establishing a sustainable antibody distribution entity. Joseph has held numerous senior positions at protein-focused companies driving strategies to maximize industry impact and profitability.

Prior roles include SVP of Global Sales and Marketing at Diagenode (acquired by Hologic), a life sciences company providing tools for molecular epigenetics research and infectious disease diagnostics, and Director of Sales at Abcam, a company specializing in the production and distribution of research antibodies. Joseph has a MSc in Pharmaceutical Medicine from Hibernia College, Ireland, and a BSc in Chemical Engineering from Michigan State University.

Nuclera is disrupting the protein market with their technology allowing researchers to more easily and quickly have access to proteins for their research. Their benchtop technology has the potential to greatly reduce costs and timelines associated with the drug discovery process. I’m excited to be joining the team at such an exciting phase of the journey to drive adoption of Nuclera’s eProtein Discovery.”

Joseph Bertelsen, Chief Commercial Officer

“Appointing our first Chief Commercial Officer marks an exciting step in Nuclera’s journey. With Joe’s strong track record and experience in achieving revenue growth, I look forward to partnering with him on rapidly increasing the number of protein makers that use our eProtein Discovery system to make proteins accessible.”

Dr Michael Chen, CEO and co-founder, Nuclera

For more information about Nuclera’s eProtein Discovery platform, please visit: https://www.nuclera.com/system/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Nuclera. (2024, March 14). Nuclera appoints Joseph Bertelsen as Chief Commercial Officer. News-Medical. Retrieved on December 11, 2024 from https://www.news-medical.net/news/20240314/Nuclera-appoints-Joseph-Bertelsen-as-Chief-Commercial-Officer.aspx.

  • MLA

    Nuclera. "Nuclera appoints Joseph Bertelsen as Chief Commercial Officer". News-Medical. 11 December 2024. <https://www.news-medical.net/news/20240314/Nuclera-appoints-Joseph-Bertelsen-as-Chief-Commercial-Officer.aspx>.

  • Chicago

    Nuclera. "Nuclera appoints Joseph Bertelsen as Chief Commercial Officer". News-Medical. https://www.news-medical.net/news/20240314/Nuclera-appoints-Joseph-Bertelsen-as-Chief-Commercial-Officer.aspx. (accessed December 11, 2024).

  • Harvard

    Nuclera. 2024. Nuclera appoints Joseph Bertelsen as Chief Commercial Officer. News-Medical, viewed 11 December 2024, https://www.news-medical.net/news/20240314/Nuclera-appoints-Joseph-Bertelsen-as-Chief-Commercial-Officer.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.